Press Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN to Present at the 22nd Annual Piper Jaffray Healthcare Conference

CHAPEL HILL, N.C., Nov 19, 2010 (BUSINESS WIRE) --

POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka, Pharm.D., the Company's Chairman, President and Chief Executive Officer, will present at the 22nd Annual Piper Jaffray Healthcare Conference on Tuesday, November 30, 2010 at 3:30 p.m. (EST), at the New York Palace Hotel in New York City. Dr. Plachetka's discussion will be webcast and available for replay on POZEN's home page at www.pozen.com.

About POZEN

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and a focus on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years - something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI toxicity. The lead candidate, PA32540, is being investigated for the secondary prevention of cardiovascular disease and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will launch creatively using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.

SOURCE: POZEN Inc.

POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.